Table 1 MTBs attended by survey participants
From: Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients
MTB name | Description of study/Background | Frequency of MTB | Genomics test used | References |
|---|---|---|---|---|
TARGET Nationala (NCT04723316) | Academic-led national study. Aims to match cancer patients with targeted early-phase clinical trials | Weekly MTBs held virtually | NGS of ctDNAon a blood sample and/or tumour biopsy(FoundationOne ® Liquid CDx and/or FoundationOne®CDX) | https://www.clinicaloncologyonline.net/article/S0936-6555(22)00489-7/fulltext |
CUP-COMPb (NCT04750109) | Academic-led national study. Compares the feasibility of molecular profiling from both tissue and blood in CUP patients | Monthly MTBs held virtually | NGS of ctDNA (FoundationOne® Liquid CDx) or tumour tissue (FoundationOne®CDX or WGS) | |
DETERMINEc (NCT05722886) | Academic-led national study. Aims to test approved targeted therapies in unlicensed indications | Weekly MTBs held virtually | No genomic testing through this study – Patient’s samples undergo genomic testing at local Genomics Laboratory Hub (GLH) as per the National genomic test directory for cancer (https://www.england.nhs.uk/publication/national-genomic-test-directories/) or within other molecular screening programmes such as TARGET National | |
Genomic Tumour Advisory Boards (GTABs) | NHS-led standard of care advisory boards that discuss patients eligible for WGS | Regional virtual meetings | WGS as per NHS National genomic test directory | |
Precision-Pancd (NCT04161417) | Master protocol. UK-wide platform for patients with known or suspected pancreatic cancer. Facilitates real-time profiling of pancreatic cancer patients for therapeutic and research purposes. | Virtual meetings held every 6 weeks | Illumina NGS technology. Targeted capture sequencing is carried out using the Glasgow Precision Oncology Laboratory (GPOL) Clinical Cancer Genome (CCG), a bespoke pancreatic cancer-specific multiplex assay accompanied by a purpose-built analysis pipeline (termed HOLMES), using publicly available and proprietary software developed in-house | https://www.clinicaloncologyonline.net/article/S0936-6555(19)30291-2/fulltext |
Integrating Medically Actionable Genomics INto Early-phase trials (IMAGINE) (NCT42303887) | Glasgow ECMC-led project. Discussion of NGS reports from patients across Scotland to inform early-phase clinical trial selection. | Fortnightly MTBs held virtually | Illumina NGS analysis of tumours by in-house ‘Cancer-plus’ panel | |
Cancer Core Europe Basket of Baskets (NCT03767075) | Platform trial from Cancer Core Europe (CCE). Part 1 includes molecular profiling programme and an MTB. Part 2 includes a basket trial. | Weekly MTBs held virtually | CCE 350-gene NGS panel |
